Pineal hormone melatonin as an adjuvant treatment for COVID‑19 (Review)
| Autor: | Angeliki Siamidi, Aikaterini Dedeloudi, Marilena Vlachou, Ioannis Papanastasiou, Sofia K. Konstantinidou |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
endocrine system pineal hormone medicine.medical_treatment melatonin Pharmacology Neuroprotection Melatonin 03 medical and health sciences 0302 clinical medicine Genetics medicine Animals Humans Cardioprotective Agent clinical trials Chronobiology SARS-CoV-2 business.industry COVID-19 Articles General Medicine Molecular medicine COVID-19 Drug Treatment Clinical trial 030104 developmental biology 030220 oncology & carcinogenesis business Adjuvant hormones hormone substitutes and hormone antagonists mechanism of action Hormone medicine.drug |
| Zdroj: | International Journal of Molecular Medicine |
| ISSN: | 1791-244X 1107-3756 |
| DOI: | 10.3892/ijmm.2021.4880 |
| Popis: | The beneficial properties of the pineal hormone, melatonin, as a neuroprotective and cardioprotective agent, have been previously identified. Furthermore, melatonin plays essential roles in biological rhythms resynchronization, sleep initiation/maintenance and metabolic, ocular, rheumatological diseases. In addition to these functions, melatonin is known to exert immunomodulation, anti-inflammatory and anti-oxidative effects. Due to these properties, coupled with its non-toxic nature, melatonin has been suggested to limit viral infections; however, melatonin cannot be classified as a viricidal drug. In addition, the recent increase in the number of clinical trials on melatonin's role, as an adjuvant treatment for COVID-19, has resurged the interest of the scientific community in this hormone. The present short review aimed to improve the understanding of the antiviral/anti-COVID-19 profile of melatonin and the clinical trials that have recently been conducted, with respect to its co-administration in treating individuals with COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|